Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Abstract

These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.